SANDSCONNECT

Overview

SANDSCONNECT is the manufacturer-facing dispensing brand of SandsRx, a family-owned specialty and compounding pharmacy headquartered in Wylie, Texas with additional Texas and Georgia sites. The clearest public proof point is direct-to-patient home delivery for Eton’s Hemangeol program; SandsRx also operates PCAB-accredited compounding labs with 50-state licensure.

SANDSCONNECT is not a national LDD network anchor or a full-stack hub. It is a smaller, high-touch specialty and compounding pharmacy buyers shortlist when the program needs niche dispensing, compounded preparations, or home delivery for a narrowly-defined therapy population.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, SANDSCONNECT is evaluated as manufacturer-facing dispensing brand of SandsRx, a family-owned specialty and compounding pharmacy headquartered in Wylie, Texas with additional Texas and Georgia sites.

Capability	Buyer should compare	SANDSCONNECT readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core. 50-state licensure with direct-to-patient delivery; documented program example is Eton’s Hemangeol Direct fulfillment.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Documented for manufacturer programs. Defined within the Hemangeol Direct workflow; ask for therapy-specific BI / PA SLAs in the RFP.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Niche-fit. Positioned as a high-touch clinical and fulfillment partner rather than a broad disease-team operator; validate per-therapy protocol depth.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Core for cold chain. Cold-chain and temperature-sensitive shipping; PCAB-accredited sterile and non-sterile compounding via the eNavvi partnership.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Confirm reporting layer in the RFP. Reporting depth is not a public differentiator; specify data fields, cadence, and reconciliation rights in the SOW.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent. Home delivery is core; infusion and health-system capture are not part of the public model. Treat as out of scope unless confirmed.

Buyer Fit

• Commercial fit trigger: A manufacturer launching a narrow, prescriber-direct therapy (dermatology, hematology, cardiology niche, fertility, HRT, or weight-management) that needs a single dispensing-and-compounding pharmacy partner rather than a national LDD network.
• Best-fit buyers: Mid-cap and biotech access teams running a single-product or small-portfolio launch, plus prescribers who already route to SandsRx for compounded preparations.
• Less ideal fit: Brands that need payer-routing scale, broad limited-distribution network presence, or PBM-owned formulary leverage.
• Commercial fit: Pricing is undisclosed; assume an RFP-led scope with service levels, data feeds, launch timing, and governance defined in the SOW.
• Profile signal: SANDSCONNECT shows up in manufacturer access programs where compounded or specialty preparations need to ship direct to patient under a named brand workflow; ownership is family-held with no PBM, payer, wholesaler, or health-system parent.
• Coverage diligence: Confirm payer-mix access, hub handoffs, REMS scope, manufacturer data cadence, and SOW boundary between SANDSCONNECT, eNavvi, and any external hub.

Differentiators

• PCAB-accredited compounding labs: Sterile and non-sterile compounding licensure across dermatology, weight-management, and HRT categories expanded under the 2026 eNavvi partnership.
• 50-state dispensing licensure: Patient-direct shipping coverage across all states without a multi-pharmacy network handoff.
• Hemangeol Direct program example: A documented manufacturer-facing fulfillment role for an Eton pediatric cardiology product, including direct home delivery and the supporting patient workflow.
• Family-owned, independent ownership: No PBM, payer, wholesaler, or health-system parent; channel-conflict diligence is simpler than with vertically-integrated specialty pharmacies.
• eNavvi digital prescription integration: Embedded into the eNavvi e-prescribing platform for compounded sterile and non-sterile categories, shortening prescriber-to-dispense routing.

RFP Questions

• Which payer plans and LDD relationships can SANDSCONNECT actually access for this specific product?
• How will benefit investigation, prior authorization, appeals, and financial-assistance routing be staffed and reported on this program?
• What therapy-specific clinical protocol, pharmacist cadence, refill outreach, and escalation model will apply versus a default workflow?
• Which compounded preparations, REMS requirements, or cold-chain workflows are handled in-house versus through eNavvi or other partners?
• How frequently will dispense, abandonment, refill, and adherence data be delivered to the manufacturer, and in what format?
• What manufacturer-program references can SandsRx provide beyond the Hemangeol Direct case, with comparable therapy-area scope?
• How are payer-mandated transfers to a different specialty pharmacy handled, and what data continues to flow back to the manufacturer in that case?

Recent Activity

• 2026-01 - eNavvi announced a partnership with SandsRx to expand sterile and non-sterile compounding for dermatology, weight-management, and HRT prescribers.
• 2025-2026 - SandsRx continued operating its multi-site footprint across Texas and Georgia, supporting specialty and compounded therapy fulfillment.